Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06096779 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis

Study acronym: Kirros
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites reduced: 59 → 54 locations Eligibility criteria expanded, about 41 words Show 1 more changeShow less
    • Eligibility criteria expanded, about 41 words
  2. Trial status changed: Recruiting → Active, Not Recruiting Trial sites reduced: 62 → 59 locationsv32 Show 1 more changeShow less
    • Trial sites reduced: 62 → 59 locations
  3. Study sites: 61 to 62v31
  4. Study sites revised (61)v30 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv29
Show 27 earlier versionsHide 27 earlier versions
  1. Study sites revised (61)v28 See this version in full on ClinicalTrials.gov ↗
  2. Study sites revised (61)v27 See this version in full on ClinicalTrials.gov ↗
  3. Primary completion date: Sep 30, 2026 to Jul 30, 2027 Primary endpoint revised · Completion date: Nov 16, 2026 to Dec 30, 2027 · Eligibility criteria expanded, about 44 words · 2 morev26 Show 5 more changesShow less
    • Primary endpoint revised
    • Completion date: Nov 16, 2026 to Dec 30, 2027
    • Eligibility criteria expanded, about 44 words
    • Study sites revised (61)
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  4. Study sites revised (61)v25 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 5 of 61 sitesv24
  6. 2 versions Re-verified since Oct 15, 2025, no change to tracked fieldsv22-v23
  7. Site details revised at 1 of 61 sitesv21
  8. 3 versions Re-verified since Jun 19, 2025, no change to tracked fieldsv18-v20
  9. Enrollment target: 120 to 30 Study sites: 60 to 61 · Eligibility criteria expanded, about 98 words · Secondary endpoints shortened, about 42 words · 2 morev17 Show 5 more changesShow less
    • Study sites: 60 to 61
    • Eligibility criteria expanded, about 98 words
    • Secondary endpoints shortened, about 42 words
    • Study title revised
    • Study description shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  10. Study sites: 59 to 60 Primary completion date: May 2, 2026 to Sep 30, 2026v16 Show 1 more changeShow less
    • Primary completion date: May 2, 2026 to Sep 30, 2026
  11. Study sites: 58 to 59v15
  12. Study sites: 56 to 58v14
  13. Study sites: 43 to 56v13
  14. Study sites: 36 to 43 Eligibility criteria expanded, about 13 words · Secondary endpoints revised (8)v12 Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints revised (8)

    See this version in full on ClinicalTrials.gov ↗

  15. Study sites: 27 to 36 Start date changed from estimate of Jun 30, 2024 to Jul 15, 2024v11 Show 1 more changeShow less
    • Start date changed from estimate of Jun 30, 2024 to Jul 15, 2024
  16. Start date: May 31, 2024 to Jun 30, 2024 Study sites: 23 to 27v10 Show 1 more changeShow less
    • Study sites: 23 to 27
  17. Study sites: 17 to 23v9
  18. Start date: Apr 11, 2024 to May 31, 2024 Study sites: 6 to 17v8 Show 1 more changeShow less
    • Study sites: 6 to 17
  19. Study sites: 3 to 6 Start date: Mar 29, 2024 to Apr 11, 2024v7 Show 1 more changeShow less
    • Start date: Mar 29, 2024 to Apr 11, 2024
  20. Study sites: 2 to 3 Start date: Feb 29, 2024 to Mar 29, 2024v6 Show 1 more changeShow less
    • Start date: Feb 29, 2024 to Mar 29, 2024
  21. Study sites: 1 to 2 Start date: Jan 31, 2024 to Feb 29, 2024v5 Show 1 more changeShow less
    • Start date: Jan 31, 2024 to Feb 29, 2024
  22. Start date: Dec 29, 2023 to Jan 31, 2024v4
  23. Start date: Nov 22, 2023 to Dec 29, 2023v3
  24. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Nov 16, 2023 to Nov 22, 2023v2 Show 2 more changesShow less
    • Study sites: 0 to 1
    • Start date: Nov 16, 2023 to Nov 22, 2023
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Roche/Genentech
366 trials monitored
See 33 trials at risk
Liver Cancer
1,512 trials monitored
See 63 trials at risk
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-pugh B7 or B8 cirrhosis.
Trial Details
NCT Number NCT06096779
Lead Sponsor Genentech, Inc.
Conditions Hepatocellular Carcinoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov